Reported / Citable
Background
Vertigo Vapor and Max & Zach’s Vapor Shops joined several consolidated petitions challenging FDA marketing denial orders involving electronic nicotine delivery system products. Under the Tobacco Control Act, a new tobacco product may be marketed only if FDA determines that doing so would be appropriate for the protection of the public health, considering both the likelihood that existing tobacco users will stop and the likelihood that nonusers will begin.
FDA applied a comparative-efficacy standard requiring evidence that flavored products would benefit adult smokers enough, relative to tobacco-flavored products, to outweigh their risks to youth. The petitioners argued that FDA had effectively made comparative-efficacy evidence a binding prerequisite for authorization through internal memoranda and repeated adjudications, without using the Administrative Procedure Act’s notice-and-comment process. Earlier decisions foreclosed their arguments that FDA had unlawfully changed its position and that the standard was a “tobacco product standard” under the Tobacco Control Act, but had expressly left the APA procedural question unresolved.
The Court’s Holding
The Fifth Circuit held that FDA’s comparative-efficacy standard was a substantive rule subject to the APA’s notice-and-comment requirements. The court reasoned that the standard applied prospectively to an open-ended class of applicants, affected regulated parties’ rights and obligations, and constrained FDA reviewers’ discretion. Internal memoranda, the agency’s treatment of more than one million marketing applications, and the very low authorization rate for flavored products supported the conclusion that the standard operated as a binding, across-the-board rule rather than a flexible policy developed case by case.
The court further held that FDA could not avoid notice and comment by embedding the rule in informal adjudications of individual applications. Although agencies generally may develop policy through either rulemaking or adjudication, the court concluded that FDA had developed a rigid, generally applicable evidentiary requirement behind closed doors and then applied it through proceedings that gave manufacturers no meaningful opportunity to address the new standard. The court granted the petitions for review, vacated the marketing denial order, and remanded without directing what FDA or the petitioners must do next.
Key Takeaways
- An agency standard that prospectively binds decision-makers and governs an unlimited class of regulated parties may be a substantive rule requiring APA notice and comment.
- An agency’s general authority to develop policy through adjudication does not permit it to impose a rigid, broadly applicable substantive rule through informal adjudications.
- FDA may reconsider the comparative-efficacy standard, adopt it through a compliant notice-and-comment process, or pursue other appropriate proceedings on remand.
Why It Matters
The decision limits FDA’s ability to use individual marketing decisions to establish generally binding evidentiary requirements for e-cigarette applicants. It also clarifies in the Fifth Circuit that courts will examine how an agency policy actually operates—not merely how the agency labels it—when deciding whether notice-and-comment rulemaking was required.
The ruling does not decide whether flavored products satisfy the statutory public-health standard or whether FDA must authorize them. Its immediate effect is procedural: the challenged denial order is vacated, and FDA must decide how to proceed consistently with the APA.